CASI Pharmaceuticals, Inc. (CASIF)
Full history for every metric is available with a Kvantra account
No price history available.
Key financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | $m | 15 | 30 | 43 | 34 | 29 | 21 | 20 | 20 |
| Operating profit | $m | -43 | -38 | ||||||
| Net profit | $m | -48 | -37 | -41 | -27 | -39 | -48 | -44 | -26 |
| EPS reported | $ | -2.59 | -2.29 | ||||||
| Operating cashflow per share | $ | -1.12 | 0.00 | ||||||
| Capex per share | $ | 0.00 | 0.00 | ||||||
| FCF per share | $ | -1.12 | 0.00 | ||||||
| Free cash flow | $m | -21 | 0 | ||||||
| Net debt | $m | 20 | 37 | ||||||
| Book value equity | $m | -37 | -58 | ||||||
| Book value per share | $ | -2.01 | -2.83 | ||||||
| Number of shares | m | 18.54 | 20.56 | ||||||
| DPS (TTM paid) | $ | 0.00 | 0.00 |
Financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E TTM | x | - | - | ||||||
| P/B LTM | x | -0.42 | -0.27 | ||||||
| P/S LTM | x | 0.76 | 0.78 | ||||||
| P/FCF LTM | x | -0.76 | 0.00 | ||||||
| EV/EBITDA LTM | x | -0.86 | -0.97 | ||||||
| EV/Sales LTM | x | 1.82 | 1.98 | ||||||
| Earnings Yield LTM | % | -3.05% | -14.26% | ||||||
| FCF Yield | % | -131.81% | 0.00% | ||||||
| Quality | |||||||||
| ROE | % | +128.90% | +96.40% | ||||||
| ROIC | % | -21.16% | +7.60% | ||||||
| Operating margin | % | -2.07% | -1.91% | ||||||
| Gross margin | % | +48.56% | +59.97% | ||||||
| FCF/Sales | % | -100.28% | 0.00% | ||||||
| Growth and momentum | |||||||||
| EPS Growth YoY | % | - | - | ||||||
| Sales Growth YoY | % | -27.42% | -29.52% | ||||||
| Net Income Growth YoY | % | - | - | ||||||
| FCF Growth | % | - | - | ||||||
| Operating Profit Growth | % | - | - | ||||||
| Dividend and capital structure | |||||||||
| Dividend Yield | % | 0.00% | 0.00% | ||||||
| Dividend Growth | % | -100.00% | -100.00% | ||||||
| Payout Ratio | % | 0.00% | 0.00% | ||||||
| FCF/Debt | x | -0.76 | 0.00 | ||||||
| Net Debt/EBITDA | x | -0.50 | -0.95 | ||||||
| EBIT/Net interest | x | -51.01 | -96.28 | ||||||
| Net debt/market cap | % | +1.65% | +13.13% | ||||||
| Net debt/Equity | x | -0.55 | -0.63 | ||||||
| Gross debt/equity | x | -0.74 | -0.70 | ||||||
Price target estimates
Based on consensus from external analysts. Not Kvantra's opinion.
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
ESG
| Metric | 2024 | 2025 | 2026 |
|---|---|---|---|
| ESG-score | |||
| Environmental score | |||
| Social score | |||
| Governance score | |||
| Risk rating |
Company overview
CASI Pharmaceuticals, Inc. operates as a biopharmaceutical firm, focusing on the development and commercialization of therapeutic and pharmaceutical products across the People's Republic of China, the United States, and international territories. The company's offerings include EVOMELA, an intravenous formulation of melphalan, which serves as a conditioning treatment before stem cell transplantation and as palliative care for patients with multiple myeloma. Its hematology/oncology pipeline is robust, featuring CNCT19, an investigative autologous CD19 CAR-T product; BI-1206, a novel anti-FcγRIIB antibody designed for treating solid tumors and relapsed/refractory non-Hodgkin lymphoma; CB-5339, an innovative VCP/p97 inhibitor targeting valosin-containing protein (VCP)/p97 pathways crucial for protein homeostasis, DNA damage response, and cellular stress in various malignancies; CID-103, a human IgG1 anti-CD38 monoclonal antibody; and Thiotepa, a chemotherapeutic agent with diverse indications, including its use as a conditioning regimen prior to certain allogeneic hematopoietic stem cell transplants. CASI Pharmaceuticals maintains licensing agreements with entities such as Juventas Cell Therapy Ltd., BioInvent International AB, Black Belt Therapeutics Limited, Cleave Therapeutics, Inc., and Acrotech Biopharma L.L.C., primarily for the development and commercialization of its commercial product, EVOMELA. The company was founded in 1991 and is headquartered in Beijing, People's Republic of China.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
No price history available.
Consensus from external analysts. Not Kvantra's opinion.
Based on consensus from external analysts. Not Kvantra's opinion.
CASI Pharmaceuticals, Inc. operates as a biopharmaceutical firm, focusing on the development and commercialization of therapeutic and pharmaceutical products across the People's Republic of China, the United States, and international territories. The company's offerings include EVOMELA, an intravenous formulation of melphalan, which serves as a conditioning treatment before stem cell transplantation and as palliative care for patients with multiple myeloma. Its hematology/oncology pipeline is robust, featuring CNCT19, an investigative autologous CD19 CAR-T product; BI-1206, a novel anti-FcγRIIB antibody designed for treating solid tumors and relapsed/refractory non-Hodgkin lymphoma; CB-5339, an innovative VCP/p97 inhibitor targeting valosin-containing protein (VCP)/p97 pathways crucial for protein homeostasis, DNA damage response, and cellular stress in various malignancies; CID-103, a human IgG1 anti-CD38 monoclonal antibody; and Thiotepa, a chemotherapeutic agent with diverse indications, including its use as a conditioning regimen prior to certain allogeneic hematopoietic stem cell transplants. CASI Pharmaceuticals maintains licensing agreements with entities such as Juventas Cell Therapy Ltd., BioInvent International AB, Black Belt Therapeutics Limited, Cleave Therapeutics, Inc., and Acrotech Biopharma L.L.C., primarily for the development and commercialization of its commercial product, EVOMELA. The company was founded in 1991 and is headquartered in Beijing, People's Republic of China.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free